$FibroGen (FGEN.US)$ NEWS FibroGen Reports First Quarter 202...
NEWS
FibroGen Reports First Quarter 2024 Financial Results
FibroGen, Inc. (NASDAQ: FGEN) reported strong financial results for Q1 2024, showing a 55% year-over-year net revenue growth driven by roxadustat sales in China and one-time revenue from the termination of the US/RoW AstraZeneca agreement. The company has a healthy cash balance of $214.7 million, ensuring financial stability till 2026.
55% year-over-year net revenue growth in Q1 2024.
Robust roxadustat sales in China with a 39% volume growth.
$214.7 million cash balance ensuring financial stability till 2026.
Compelling Phase 1 data on FG-3246 in metastatic castration-resistant prostate cancer.
Expected topline data from late-stage clinical trials of pamrevlumab in pancreatic cancer in mid-2024 and 3Q 2024.
Robust roxadustat sales in China with a 39% volume growth.
$214.7 million cash balance ensuring financial stability till 2026.
Compelling Phase 1 data on FG-3246 in metastatic castration-resistant prostate cancer.
Expected topline data from late-stage clinical trials of pamrevlumab in pancreatic cancer in mid-2024 and 3Q 2024.
Net loss of $32.9 million in Q1 2024.
25.7 million one-time revenue due to the termination of the US/RoW AstraZeneca agreement.
Expected approval decision for roxadustat in chemotherapy-induced anemia (CIA) in China in the second half of 2024.
25.7 million one-time revenue due to the termination of the US/RoW AstraZeneca agreement.
Expected approval decision for roxadustat in chemotherapy-induced anemia (CIA) in China in the second half of 2024.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
634Followers
74Following
4056Visitors
Follow
Travelforfreedom : Sure fly, bingo. Fly downwards